A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Denileukin diftitox, a genetically engineered fusion protein combining the enzymatically active domains of diphtheria toxin and the full-length sequence for interleukin-2 (IL-2), efficiently targets lymphoma cells expressing the high-affinity IL-2 receptor (IL-2R) consisting of the α/p55/CD25, β/p75/CD122, and γ/p64/CD132 chains. In vitro studies demonstrated that the retinoid X receptor (RXR) retinoid, bexarotene, at biologically relevant concentrations of 10–6M to 10–8 M, upregulated both the p55 and p75 subunits of the IL-2R and enhanced 5- to 10-fold the susceptibility of T-cell leukemia cells to denileukin diftitox. To determine whether this biomodulatory effect could be recapitulated in vivo, we treated 14 patients with relapsed or refractory cutaneous T-cell lymphoma with escalating doses of bexarotene (75 mg/day-300 mg/day) and denileukin diftitox (18 mcg/kg per day × 3 days every 21 days) in a phase 1 trial. Overall response was 67% (4 complete responses, 4 partial responses). Modulation of IL-2R expression was observed at or above a bexarotene dose of 150 mg/day. Four patients experienced grade 2 or 3 leukopenia, and 2 had grade 4 lymphopenia. Our results demonstrate that the combination of denileukin diftitox and bexarotene is well tolerated and that even low doses (150 mg/day) of bexarotene are capable of in vivo upregulation of CD25 expression on circulating leukemia cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Duvic, M., Hymes, K., Heald, P., Breneman, D., Martin, A. G., Myskowski, P., Crowley, C., Yocum, R. C., & for Members of the Bexarotene Worldwide Study Group (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.9.2456 · Cited by 706
Cited by
Pastan, I., Hassan, R., FitzGerald, D. J., & Kreitman, R. J. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1891 · Cited by 528
(2010) · Advances in Cancer Research · doi:10.1016/s0065-230x(10)07003-x · Cited by 386
Immunotoxin Treatment of Cancer
Pastan, I., Hassan, R., FitzGerald, D. J., & Kreitman, R. J. (2007) · Annual Review of Medicine · doi:10.1146/annurev.med.58.070605.115320 · Cited by 359
Zelenetz, A. D., Abramson, J. S., Advani, R. H., Andreadis, C. B., Byrd, J. C., Czuczman, M. S., Fayad, L., Forero, A., Glenn, M. J., Gockerman, J. P., et al. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0021 · Cited by 329
Mycosis fungoides and Sézary syndrome
Hwang, S. T., Janik, J. E., Jaffe, E. S., & Wilson, W. H. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60420-1 · Cited by 286
Metadata
- Authors
- Foss, F., Demierre, M. F., & DiVenuti, G.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2005-07-15
- Volume
- 106
- Issue
- 2
- Pages
- 454-457
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W1986419116
- Cited by
- 114
- References
- 1
- FWCI
- 16.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma. https://app.cochat.ai/papers/10.1182/blood-2004-11-4570
- The paper
- Foss, F., Demierre, M. F., & DiVenuti, G. (2005). A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood. https://doi.org/10.1182/blood-2004-11-4570
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.